Galapagos Genomics

Galapagos Genomics NV is a biotech company located in Mechelen, Belgium. The company was founded in 1999 as a joint venture between Crucell (formerly IntroGene) and Tibotec. The company has its own internal discovery programs which it combines with drug discovery and pre-clinical service activities for other biotech and pharmaceutical companies.

The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.